The stock of AnaptysBio Inc (ANAB) has gone down by -11.57% for the week, with a -13.34% drop in the past month and a 33.53% rise in the past quarter. The volatility ratio for the week is 6.39%, and the volatility levels for the past 30 days are 5.22% for ANAB. The simple moving average for the past 20 days is -12.41% for ANAB’s stock, with a 22.58% simple moving average for the past 200 days.
Is It Worth Investing in AnaptysBio Inc (NASDAQ: ANAB) Right Now?
The 36-month beta value for ANAB is at -0.28. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ANAB is 25.82M, and currently, shorts hold a 22.59% of that float. The average trading volume for ANAB on September 26, 2024 was 316.78K shares.
ANAB) stock’s latest price update
The stock price of AnaptysBio Inc (NASDAQ: ANAB) has dropped by -7.28 compared to previous close of 34.88. Despite this, the company has seen a fall of -11.57% in its stock price over the last five trading days. globenewswire.com reported 2024-08-29 that SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
Analysts’ Opinion of ANAB
Many brokerage firms have already submitted their reports for ANAB stocks, with H.C. Wainwright repeating the rating for ANAB by listing it as a “Buy.” The predicted price for ANAB in the upcoming period, according to H.C. Wainwright is $55 based on the research report published on July 22, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see ANAB reach a price target of $69, previously predicting the price at $29. The rating they have provided for ANAB stocks is “Overweight” according to the report published on July 19th, 2024.
Leerink Partners gave a rating of “Outperform” to ANAB, setting the target price at $47 in the report published on April 16th of the current year.
ANAB Trading at -9.47% from the 50-Day Moving Average
After a stumble in the market that brought ANAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.71% of loss for the given period.
Volatility was left at 5.22%, however, over the last 30 days, the volatility rate increased by 6.39%, as shares sank -12.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.21% lower at present.
During the last 5 trading sessions, ANAB fell by -11.57%, which changed the moving average for the period of 200-days by +96.95% in comparison to the 20-day moving average, which settled at $36.70. In addition, AnaptysBio Inc saw 50.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANAB starting from Lizzul Paul F., who sale 1,500 shares at the price of $38.67 back on Sep 23 ’24. After this action, Lizzul Paul F. now owns 15,398 shares of AnaptysBio Inc, valued at $58,005 using the latest closing price.
PAUL F LIZZUL, the Officer of AnaptysBio Inc, proposed sale 1,500 shares at $38.67 during a trade that took place back on Sep 23 ’24, which means that PAUL F LIZZUL is holding shares at $58,005 based on the most recent closing price.
Stock Fundamentals for ANAB
Current profitability levels for the company are sitting at:
- -5.33 for the present operating margin
- 0.92 for the gross margin
The net margin for AnaptysBio Inc stands at -5.58. The total capital return value is set at -0.42. Equity return is now at value -214.89, with -36.02 for asset returns.
Based on AnaptysBio Inc (ANAB), the company’s capital structure generated 0.97 points at debt to capital in total, while cash flow to debt ratio is standing at -0.36. The debt to equity ratio resting at 36.83. The interest coverage ratio of the stock is -6.09.
Currently, EBITDA for the company is -135.82 million with net debt to EBITDA at -2.04. When we switch over and look at the enterprise to sales, we see a ratio of 42.13. The receivables turnover for the company is 3.38for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.09.
Conclusion
In conclusion, AnaptysBio Inc (ANAB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
